Differential gene expression profile of newly diagnosed versus relapse acute promyelocytic leukemia

The aim of this study was to gain insight into the potential mechanism of resistance to arsenic trioxide and to identify genes that are modulated in the malignant promyelocytes at the time of relapse in APL patients. We analyzed the gene expression profile by the whole genome microarray of primary promyelocytes obtained from 8 newly diagnosed and 8 at relapse patients. Agilent one-color experiment,Organism: Human ,Agilent Whole Genome Human 4x44k (AMADID: 014850) , Labeling kit: Agilent Quick-Amp labeling Kit (p/n5190-0442) newly diagnosed versus relapse acute promyelocytic leukemia

本研究旨在阐明三氧化二砷（arsenic trioxide）耐药的潜在分子机制，并鉴定急性早幼粒细胞白血病（APL）患者复发阶段其恶性早幼粒细胞内表达发生调控改变的基因。本研究通过全基因组微阵列技术，对8名初诊急性早幼粒细胞白血病患者与8名复发急性早幼粒细胞白血病患者的原发性早幼粒细胞的基因表达谱进行分析。实验采用安捷伦（Agilent）单通道微阵列方案，实验生物为人类（Human），所用芯片为安捷伦全基因组人类4x44k芯片（AMADID: 014850），标记试剂盒为安捷伦Quick-Amp标记试剂盒（货号p/n5190-0442），比较组别为初诊与复发急性早幼粒细胞白血病样本。